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Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvas-
cular obstruction may persist as a result of both atheromatous and thrombotic emboli-
zation and vasospasm. Compared with the systemic administration of IV pharmaco-
therapies, highly localized administration of intracoronary pharmacotherapy may be
associated with a several-hundred-fold increase in the local concentration of an agent in
the epicardial artery and microcirculation. Despite restoration of epicardial flow during
primary PCI in STEMI, microvascular obstruction may persist as a result of both athero-
matous and thrombotic embolization and vasospasm. We are presenting our experience
with use of intracoronary abciximab using local drug delivery catheter in STEMI patients.
Methods: We retrospectively evaluated 15 patients presented to us with STEMI undergoing
primary PCI between March 2011 and September 2012 who had super selective intra-
coronary abciximab using local drug delivery catheter. With standard antiplatelet therapy,
both Pre and Post TIMI flow, TMP grading were assessed.
Results: Mean age was 55 years. The TIMI flow increased by 3 grades in thirteen patients,
TMP grading increased by 2 grades in five patients and by 3 grades in nine patients. Thus
TIMI flow and TMP grading improved after super selective intracoronary abciximab.
Conclusion: Super selective intracoronary abciximab using local drug delivery catheter
during primary PCI in STEMI patients significantly improves TMP grading without
increased risk of bleeding. This benefit is achieved even in patients without thrombus
aspiration. We need to assess the long-term outcomes in the form of reduction in infarct
size using this strategy in large group of patients.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction introduced. Despite restoration of epicardial flow, microvas-Primary percutaneous coronary intervention (PCI) is now the
preferred method of treating patients with ST elevation
myocardial infarction (STEMI). The results of primary PCI
have improved continuously since the technique wasengottuvelu).
2013, Cardiological Sociecular obstruction may persist after primary PCI as a result of
both atheromatous and thrombotic embolization, neutrophil
plugging, edema, and vasospasm.1
There have been efforts to identify mechanical and phar-
macological strategies to improve myocardial perfusion afterty of India. All rights reserved.
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been accompanied by a notable development in associated
drug treatments. Compared with the systemic administration
of intravenous pharmacotherapies, highly localized adminis-
tration of intracoronary pharmacotherapy may be associated
with a several-hundred-fold increase in the local concentra-
tion of an agent in the epicardial artery and microcirculation.
We are presenting herewith our center experience with
intracoronary abciximab in STEMI using clearway catheter
and assessed the outcomes using TIMI flow and TMP grading.2. Methods
Weassessed 15 consecutive patientswho presented to uswith
STEMI undergoing emergency primary PCI between March
2011 and September 2012. All patients received loading dose of
aspirin and 600 mg clopidogrel. Thrombus aspiration was
done whenever the thrombus burden was huge. All patients
were given bolus only dose of intracoronary abciximab
(0.25 mg/kg) using the clearway catheter.
The clearway therapeutic perfusion catheter (Maquet car-
diovascular, Sweden) acts as a low-pressure irrigating system
for localized perfusion of therapeutic agents into the coronary
vasculature. It is a semi compliant micro porous PTFE balloon
mounted on 2.7 F Rx catheter and will not burst or tear during
use. Fluid gently weeps through the pores with no high pres-
sure jetting. It inflates and infuses fluid at low pressure
(1e4 atm) and does not damage the internal elastic lamina of
vessel during inflation and infusion. Pressure at balloon sur-
face during infusion is nearly zero relative to blood pressure.
Balloon inflation causes occlusion of the vessel providing a
better drug contact with thrombus without dilution by blood
flow increasing concentration and residence time, which
leads to a greater reduction in TIMI thrombus burden score, a
hallmark of this therapy. This local drug delivery catheter
system is described as OCI (Occlusion, Containment, Infusion)
therapeutics allowing site specific, localized drug delivery
across any coronary lesion. The potential disadvantage of
traditional method (passing through guide catheter) is >50%
of the drug will be washed away in systemic circulation and
other 20e25% drugs will be delivered to unwanted branches.
Less than 20% of the drug will reach the target lesion.
Pre TIMI flow and TMP grading were assessed. The
improvement of TIMI flow and TMP grade after intracoronary
abciximab using clearway catheter were assessed. After
aspiration and abciximab treatment using local drug delivery,
stent was deployed using standard protocol.Table 1 e Patient and procedure characteristics.










Thrombus aspiration 63. Results
The study population (Mean age of 55  11 years) had 15 pa-
tients with STEMI.
Bivalirudin anticoagulation was used in 33% (5/15) during
the procedure. Majority of study patients had AWMI 60%.
Mean window period of presentation is 7.5 h. One patient had
no requirement for stent as angiographically it was a stent like
result. 93% (14/15) of them had TIMI 0 flow pre PCI while the
rest 7% (1/15) had TIMI 1 flow (Table 1). The TIMI flowincreased by 2 grade in 2 patients and by 3 grades in 13 pa-
tients. The TMP grading increased by 1 grade in 1 patient, by 2
grade in 5 patients and by 3 grade in 9 patients. TIMI flow
remained the same or worsened in none of the patients. 93%
(14/15) patients had TIMI 3 flow post procedure with no in-
hospital mortality. Clinical/telephonic follow up was done
for all patients and there was zero MACE at 30 days.4. Discussion
Potent inhibition of platelet aggregation can be achieved by
the use of intravenous glycoprotein IIb/IIIa inhibitors, which
inhibit the final common pathway of platelet aggregation, the
cross-bridging of platelets secondary to fibrinogen binding to
the activated GP IIb/IIIa receptor.
A 2002 meta-analysis examined 31,400 non-ST elevation
ACS patients treated with aspirin and heparin who did not
undergo early revascularization. GP IIb/IIIa inhibitor use was
associated with a significant reduction in the combined
endpoint (death or MI) at five days and at 30 days with benefit
appeared to be limited to the highest risk patients.2
An interesting observation from the PRISM, CAPTURE, and
PARAGON B trials and a meta-analysis is that the benefit from
GP IIb/IIIa inhibition primarily occurred in the subset of pa-
tients who had elevations in troponin.3e5 The same pattern of
benefit limited to patients with elevated troponins was also
noted in the ISAR-REACT 2 trial of patients also treated with
clopidogrel.6 In ISAR-REACT 2, all patients received pretreat-
ment with aspirin and 600 mg of clopidogrel. While there is
evidence to recommend GP IIb/IIIa inhibitor therapy in high-
risk patients treated with a conservative approach, the evi-
dence comes from studies performed before the routine use of
P2Y12 receptor blockers. The role of GP IIb/IIIa inhibitor for
these high-risk patients on dual oral antiplatelet therapy is
questionable in elective PCI.
However intravenous GP IIb/IIIa receptor antagonists in
conjunction with unfractionated heparin or bivalirudin has
been established to have a beneficial role in STEMI patients
undergoing primary PCI7 in whom there is no adequate time
interval for elective loading dose.
Meta-analysis have showed that IC administration of
abciximab is associatedwith significant benefits inmyocardial
perfusion and mortality at short-term follow-up compared to
IV abciximab administration, without any excess of major
bleeding in STEMI patients undergoing primary PCI.8,9
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administration is that it may be more effective, more timely
and, potentially, safer. Considering the short plasma half-life
of abciximab, mostly related to its rapid binding to exposed
GP IIb/IIIa receptors on the surface of circulating platelets,
intravenous administration of abciximab might prevent the
attainment of a suitable concentration at the culprit lesion
and in the distal bed of the culprit vessel.10 Intracoronary
administration of the bolus dose is associated with a several-
hundred-fold increase in the local concentration of an agent
in the epicardial artery and microcirculation and may prob-
ably increase the dose-dependent antiplatelet and anti-
thrombotic effects focusing on the culprit lesion.11 High local
concentrations of the drug would lead to fewer GP IIb/IIIa re-
ceptors being available for cross-linking with fibrinogen in the
coronary microcirculation and also lead to an optimization of
both IIb/IIIa and non-IIb/IIIa dependent properties.
Moreover, during PCI, the intracoronary administration of
abciximab can be easily performed due to the use of selective
coronary catheters.12 Super selective drug delivery catheters
give the highest local concentration of the drug avoiding
draining off the drug into non-culprit vessels. Localized super
selective abciximab protects from distal emboli that may have
dislodged during the initial plaque rupture and also resolves
residual thrombus that remainbehindaftermanual extraction.
Furthermore, intracoronary administration may facilitate
the diffusion of the antibody to platelets inside flow-limiting
thrombi; in fact, depending on the relation between inflow
and washout from residual perfusion and the size of the
ischemic area, the concentration of abciximab at the culprit
lesion after intracoronary injection compared with intrave-
nous bolus administrationmight vary between 280:1 (minimal
washout) and 1:1 (normal flow).
Thus, bymodulating inflammatory cell responses and their
interactions with platelets and the endothelium, abciximab
may favourably influence post-ischemic microvascular
endothelial responses leading to vessel wall passivation, a
reduced reperfusion injury and a greater degree of myocardial
salvage.
Wohrle and colleagues,13 demonstrated in a randomized
study, a significant reduction of the incidence of MACE at 30
days, using intracoronary bolus rather than intravenous in
patients with acute coronary syndromes undergoing coronary
angioplasty. A retrospective study with similar design coming
from Kakkar and colleagues14 showed similar findings,
reporting that in unselected patients undergoing coronary
stenting and abciximab administration, intracoronary bolus
injection is associated with a significantly lower 6-month
composite endpoint of death or myocardial infarction
compared to the intravenously-treated group.
In the AIDA STEMI trial,15 patients presenting with STEMI
with no contraindications for abciximab were randomly
assigned in a 1:1 ratio by randomization system to intra-
coronary via guide catheter versus intravenous bolus abcix-
imab with a subsequent 12 h intravenous infusion. The guide
catheter delivery of abciximab compared to intravenous
abciximab did not show any difference in combined endpoints
of death, re-infarction, or congestive heart failure.
In the COCTAIL study16,17 whether local abciximab delivery
to the site of thrombus through the Local drug deliverycatheter is more effective than intracoronary infusion
through the guiding catheter in primary PCI was studied. The
study found a significant reduction of thrombus burden
assessed by OCT with intracoronary abciximab using clear-
way catheter.18
INFUSE AMI trial19 was done to assess whether bolus
intracoronary abciximab, manual aspiration thrombectomy,
or both reduced infarct size in high-risk patients with STEMI.
0.25-mg/kg bolus of abciximab was administered at the site of
the infarct lesion via the clearway catheter. This study ran-
domized only large anterior MIs with TIMI 0e2 flow in prox-
imal/mid LADwith symptom onset to PCI less than 5 h aiming
at reperfusion within the time window for potential myocar-
dial salvage. Intracoronary abciximab bolus only versus no
abciximab was compared. Manual aspiration thrombectomy
was performed with a 6 F aspiration catheter. Infarct size was
assessed by MRI at 30 days, after edema had decreased. The
INFUSE-AMI results reaffirmed our treatment strategy with
intracoronary bolus only abciximab delivered to the infarct
lesion site via the local drug delivery catheter infusion cath-
eter resulted in a significant reduction in infarct size at
30 days. Manual aspiration with the 6 F Export Catheter only
did not reduce infarct size.
The recent 2013 ACC/AHA guidelines have incorporated
the role for intracoronary abciximab during primary PCI.20
In our study, the TMP grading improved significantly after
the intracoronary lesion specific abciximab irrespective of
aspiration devices. Importantly, the intracoronary adminis-
tration of abciximab was not associated with bleeding or any
side effects as only bolus dose was given.
Studies comparingmode of delivery such as site specific or
intracoronary or intravenous administration of abciximab in
STEMI are limited. But available studies report a clear benefit
of super selective intracoronary administration, with a
reduction in the short and medium-term incidence of events,
although the studies were retrospective. Our study was
consistent with the findings of the above and we found an
increase in the TMP gradingwhich in turn have been shown in
other studies as a marker for reduction in infarct size and
MACE at 30 days.5. Limitations
Our study had limited number of patients and hence to
show the benefit in real world we need randomized trials
with criterion and large numbers. We did not have a
control arm to compare the benefit without intracoronary
abciximab.6. Conclusion
Intracoronary abciximab using local drug delivery catheter in
patients with STEMI with thrombus burden significantly im-
proves TMP grading without increasing the risk of bleeding.
This benefit is achieved even in patients without thrombus
aspiration. We need to assess the long-term outcomes
demonstrating reduction in infarct size and mortality in large
trials.
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